July 6, 2022
July 6, 2022 –
The U.S. FDA has revised emergency use authorization (EAU) for Pfizer’s PaxlovidTM (nirmatrelvir and ritonavir) to allow state-licensed pharmacists
June 30, 2022
June 30, 2022 –
The U.S. FDA has issued a safety warning for Secura Bio’s Copiktra® (duvelisib), a treatment for chronic lymphocytic leukemia (CLL) and small
June 29, 2022
June 29, 2022 –
Based on recent data, the U.S. FDA has revised emergency use authorization (EUA) for
AstraZeneca’s vuseldTM (tixagevimab co-packaged with cilgavimab)
June 27, 2022
June 27, 2022 –
The U.S. FDA has approved Qsymia® (phentermine/topiramate extended-release capsules – Vivus) to provide chronic weight management in pediatric
June 24, 2022
June 24, 2022 –
The U.S. FDA has approved two new indications for Breyanzi® (lisocabtagene maraleucel),
in the treatment of large B-cell lymphoma (LBCL).
June 23, 2022
June 23, 2022 –
Tafinlar® (dabrafenib) and Mekinist® (trametinib), both made by Novartis, are now approved for combination use to treat unresectable or
June 22, 2022
June 22, 2022 –
The U.S. FDA has approved an expanded indication for VaxneuvanceTM (pneumococcal 15-
valent conjugate vaccine) to include pediatric patients
June 22, 2022
June 22, 2022 –
Zulresso (brexanolone) has obtained an expanded indication to treat postpartum depression (PPD) in patients who are at least 15 years old